within Pharmacolibrary.Drugs.ATC.L;

model L01BC06
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.55,
    Cl             = 0.00975,
    adminDuration  = 600,
    adminMass      = 2000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.186,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.01983333333333333,
    Tlag           = 15.0
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01BC06</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Capecitabine is an oral prodrug of 5-fluorouracil (5-FU), used as a chemotherapy agent primarily for the treatment of metastatic breast cancer and colorectal cancer. It is approved and widely used in clinical oncology. The drug is enzymatically converted to 5-FU preferentially in tumor tissues.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics of capecitabine in adult cancer patients (median age ~56 years, both sexes, solid tumors), following repeated oral administration of 1250 mg/m2 twice daily for 14 days in a 21-day cycle.</p><h4>References</h4><ol><li><p>Walko, CM, &amp; Lindley, C (2005). Capecitabine: a review. <i>Clinical therapeutics</i> 27(1) 23–44. DOI:<a href=\"https://doi.org/10.1016/j.clinthera.2005.01.005\">10.1016/j.clinthera.2005.01.005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15763604/\">https://pubmed.ncbi.nlm.nih.gov/15763604</a></p></li><li><p>Wetzel, S, et al., &amp; Villarino, NF (2024). A pilot study investigating plasma pharmacokinetics and tolerance of oral capecitabine in carcinoma-bearing dogs. <i>BMC veterinary research</i> 20(1) 36–None. DOI:<a href=\"https://doi.org/10.1186/s12917-023-03805-y\">10.1186/s12917-023-03805-y</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38297307/\">https://pubmed.ncbi.nlm.nih.gov/38297307</a></p></li><li><p>Dooley, M, &amp; Goa, KL (1999). Capecitabine. <i>Drugs</i> 58(1) 69–78. DOI:<a href=\"https://doi.org/10.2165/00003495-199958010-00006\">10.2165/00003495-199958010-00006</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10439930/\">https://pubmed.ncbi.nlm.nih.gov/10439930</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01BC06;
